These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 22816430

  • 1. Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity.
    Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, Goto K, Sawa Y, Nishioka Y, Kato Y.
    Cancer Sci; 2012 Nov; 103(11):1913-9. PubMed ID: 22816430
    [Abstract] [Full Text] [Related]

  • 2. Chimeric Anti-Human Podoplanin Antibody NZ-12 of Lambda Light Chain Exerts Higher Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity Compared with NZ-8 of Kappa Light Chain.
    Kaneko MK, Abe S, Ogasawara S, Fujii Y, Yamada S, Murata T, Uchida H, Tahara H, Nishioka Y, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):25-29. PubMed ID: 28157429
    [Abstract] [Full Text] [Related]

  • 3. The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity.
    Kato Y, Kunita A, Abe S, Ogasawara S, Fujii Y, Oki H, Fukayama M, Nishioka Y, Kaneko MK.
    Oncotarget; 2015 Nov 03; 6(34):36003-18. PubMed ID: 26416352
    [Abstract] [Full Text] [Related]

  • 4. Development of Core-Fucose-Deficient Humanized and Chimeric Anti-Human Podoplanin Antibodies.
    Kaneko MK, Ohishi T, Nakamura T, Inoue H, Takei J, Sano M, Asano T, Sayama Y, Hosono H, Suzuki H, Kawada M, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2020 Oct 03; 39(5):167-174. PubMed ID: 33085938
    [Abstract] [Full Text] [Related]

  • 5. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
    Abe S, Morita Y, Kaneko MK, Hanibuchi M, Tsujimoto Y, Goto H, Kakiuchi S, Aono Y, Huang J, Sato S, Kishuku M, Taniguchi Y, Azuma M, Kawazoe K, Sekido Y, Yano S, Akiyama S, Sone S, Minakuchi K, Kato Y, Nishioka Y.
    J Immunol; 2013 Jun 15; 190(12):6239-49. PubMed ID: 23690472
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.
    Cancer Sci; 2016 Sep 15; 107(9):1198-205. PubMed ID: 27294401
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
    Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2017 Jun 15; 36(3):104-112. PubMed ID: 28504613
    [Abstract] [Full Text] [Related]

  • 9. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
    Kato Y, Kunita A, Fukayama M, Abe S, Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, Saidoh N, Yoshida K, Fujii Y, Honma R, Takagi M, Ogasawara S, Murata T, Kaneko MK.
    Monoclon Antib Immunodiagn Immunother; 2017 Feb 15; 36(1):20-24. PubMed ID: 28234556
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
    Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, Kato Y.
    Cancer Med; 2017 Apr 15; 6(4):768-777. PubMed ID: 28332312
    [Abstract] [Full Text] [Related]

  • 11. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.
    Ukaji T, Takemoto A, Shibata H, Kakino M, Takagi S, Katayama R, Fujita N.
    Cancer Sci; 2021 Jun 15; 112(6):2299-2313. PubMed ID: 33735501
    [Abstract] [Full Text] [Related]

  • 12. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
    Kato Y, Mizuno T, Yamada S, Nakamura T, Itai S, Yanaka M, Sano M, Kaneko MK.
    Monoclon Antib Immunodiagn Immunother; 2018 Nov 15; 37(5):218-223. PubMed ID: 30362926
    [Abstract] [Full Text] [Related]

  • 13. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
    Ogasawara S, Kaneko MK, Price JE, Kato Y.
    Hybridoma (Larchmt); 2008 Aug 15; 27(4):259-67. PubMed ID: 18707544
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain.
    Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K, Osawa M.
    Biochem Biophys Res Commun; 2006 Nov 03; 349(4):1301-7. PubMed ID: 16979138
    [Abstract] [Full Text] [Related]

  • 15. Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin.
    Oki H, Kaneko MK, Ogasawara S, Tsujimoto Y, Liu X, Sugawara M, Takakubo Y, Takagi M, Kato Y.
    Monoclon Antib Immunodiagn Immunother; 2015 Jun 03; 34(3):174-80. PubMed ID: 26090595
    [Abstract] [Full Text] [Related]

  • 16. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin.
    Kato Y, Kaneko MK.
    Sci Rep; 2014 Aug 01; 4():5924. PubMed ID: 25080943
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.
    Sudo H, Tsuji AB, Sugyo A, Saga T, Kaneko MK, Kato Y, Higashi T.
    Cancer Sci; 2019 May 01; 110(5):1653-1664. PubMed ID: 30801908
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas.
    Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2010 Oct 01; 37(7):785-94. PubMed ID: 20870153
    [Abstract] [Full Text] [Related]

  • 19. Platelet-activating factor podoplanin: from discovery to drug development.
    Takemoto A, Miyata K, Fujita N.
    Cancer Metastasis Rev; 2017 Jun 01; 36(2):225-234. PubMed ID: 28674748
    [Abstract] [Full Text] [Related]

  • 20. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis.
    Sekiguchi T, Takemoto A, Takagi S, Takatori K, Sato S, Takami M, Fujita N.
    Oncotarget; 2016 Jan 26; 7(4):3934-46. PubMed ID: 26684030
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.